PharmaIN, founded in Bothell, United States, is a development-stage biopharmaceutical company dedicated to enhancing injectable therapeutics through its proprietary Protected Graft Copolymer (PGC™) technology. This technology, licensed from Massachusetts General Hospital, aims to extend the half-life and improve the targeted delivery of proteins, peptides, siRNA, and potent small molecule therapeutics. PharmaIN's market focus includes addressing critical needs in drug delivery systems to improve patient outcomes.
Notable affiliations include Massachusetts General Hospital, from which PharmaIN licenses its core technology. Key achievements involve the development of investigational drug therapies like PHIN-214, although these have not yet received FDA approval. The company's impact lies in its innovative approach to drug delivery, potentially transforming therapeutic efficacy and patient care in the biopharmaceutical industry.
